Skip to main content

Table 1 Clinical characteristics of study patients upon enrollmenta, per study group

From: A comparative study of time-specific oxidative stress after acute myocardial infarction in patients with and without diabetes mellitus

  non-DM DM p valueb
  n = 34 n = 34
Age (years) 62.1 ± 9.6 61.4 ± 9.9 0.739
Sex, male (%) 32 (94.1) 29 (85.3) 0.259
BMI 24.7 ± 2.5 25.3 ± 2.6 0.293
Risk factors
 Hypertension, n (%) 28 (82.4) 29 (85.3) 0.742
 Dyslipidemia, n (%) 26 (76.5) 26 (76.5) 1.000
 Smoking, n (%) 19 (55.9) 23 (67.6) 0.318
Biochemical markers
 HbA1c (%) 5.6 ± 0.3 6.6 ± 0.5 <0.001
 Fasting plasma glucose (mg/dL) 97.5 ± 7.4 114.6 ± 18.6 <0.001
 2 h OGTT plasma glucose (mg/dL) 119.8 ± 13.0 172.7 ± 33.7 <0.001
 HOMA-IR 1.53 ± 0.81 2.73 ± 1.89 <0.001
 eGFR (mL/min/1.73 m2) 63.2 ± 16.0 71.7 ± 16.5 0.035
 CPK (maximum) (U/L) 3532.2 ± 3898.3 2360.6 ± 2181.8 0.247
 hs-CRP (mg/dL) 0.654 ± 0.695 0.828 ± 0.712 0.311
 Total cholesterol (mg/dL) 199.9 ± 35.3 196.0 ± 57.4 0.954
 Triglyceride (mg/dL) 95.0 ± 55.2 127.6 ± 77.8 0.277
 HDL cholesterol (mg/dL) 46.6 ± 12.3 45.8 ± 10.0 0.825
 LDL cholesterol (mg/dL) 134.3 ± 29.5 116.7 ± 37.0 0.752
 NT-proBNP (pg/mL) 804.8 ± 1057.8 645.1 ± 915.0 0.578
Medications
 Ca channel blocker, n (%) 9 (26.5) 6 (17.6) 0.470
 Beta blocker, n (%) 19 (55.9) 18 (52.9) 0.924
 ACE-I/ARB, n (%) 22 (64.7) 25 (73.5) 0.504
 Nitrate, n (%) 30 (88.2) 18 (52.9) 0.004
 Statin, n (%) 24 (70.6) 23 (67.6) 0.853
  1. aAt 1 week after AMI onset
  2. Data are expressed as mean ± SD or number (%). bobtained by ANOVA or chi-square test. HbA1c, fasting plasma glucose, 2 h OGTT plasma glucose, HOMA-IR and eGFR levels were significantly higher and the use of nitrate was signifincatly lower in DM patients group.  DM diabetes mellitus, BMI body mass index, HbA1c hemoglobin A1c, OGTT oral glucose tolerance test, HOMA-IR homeostatic model assessment-insulin resistance, eGFR estimated glomerular filtration rate, CPK creatine phosphokinase, hs-CRP high-sensitivity C-reactive protein, HDL high density lipoprotein, LDL low density lipoprotein, NT-proBNP N-terminal prohormone of brain natriuretic peptide, ACE-I angiotensin converting enzyme inhibitor, ARB, angiotensin receptor blocker